In this enlightening interview, esteemed Oncologist Gary Schwartz, MD discusses the promising development and potential of Cabozantinib plus Nivolumab as a therapeutic approach in advanced Angiosarcoma. Drawing from his extensive experience and recent clinical trials, Dr. Schwartz delves into the efficacy and safety profile of this potent combination. He shares insights on how this regimen … Continue reading Exploring Cabozantinib Plus Nivolumab: A Breakthrough in Advanced Angiosarcoma – An Interview with Dr. Gary Schwartz